B群脑膜炎球菌疫苗(Novartis Pharma AG)(Meningococcal group B vaccine(GlaxoSmithKline Biologicals SA)) - 在研适应症：脑膜炎，脑膜炎球菌感染_专利_临床

概要

基本信息

药物类型

灭活疫苗、预防性疫苗、外膜囊泡疫苗

别名

MenB、MenB+OMV NZ、Meningococcal B recombinant vaccine

+ [8]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GSK PlcGlaxoSmithKline Vaccines SrlGlaxoSmithKline Biologicals SA

+ [1]

非在研机构

Novartis AGNovartis Vaccines & Diagnostics, Inc.

权益机构

GSK Plc

Pfizer Inc.

Novartis AG

最高研发阶段批准上市

首次获批日期

欧盟 (2013-01-13),

脑膜炎球菌感染

最高研发阶段(中国)临床申请

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 6741

Sequence Code 23917

Sequence Code 58469

关联

71

项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的临床试验

NCT07252804

/ Recruiting临床4期IIT

Short- and Long-Term Immunogenicity and Safety of Meningococcal Group B Vaccine in Children and Adolescents With Autoimmune Rheumatic Diseases

The goal of this clinical trial is to evaluate the humoral immunogenicity of the meningococcal B vaccine (MenB-4C) in pediatric patients with autoimmune rheumatic diseases (ARDs), compared to age- and sex-matched non-immunosuppressed controls.
The main questions it aims to answer are:
* To assess the influence of treatment on the response to the MenB-4C vaccine in patients with ARDs;
* To evaluate the impact of the MenB-4C vaccine on disease activity in patients with ARDs;
* To evaluate the safety of the MenB-4C vaccine in pediatric patients with ARDs and controls.
* To evaluate the association between physical activity levels and immunogenicity after vaccination.
Participants will:
Receive the MenB-4C vaccine (Bexsero©), administered intramuscularly in the deltoid muscle, in a 2-dose schedule (0.5 mL each), 1 month apart.
All participants will have blood samples collected immediately before vaccination at the baseline visit (D0), then receive the first vaccine dose on the same day (D0). The second dose will be administered 4 weeks after the first dose (D28). Blood samples will be collected on D0, D28, and D56. A final sample will be collected one year after the last dose (D208) to evaluate the persistence of immune response.
At study entry and one month after each dose, patients will also be assessed for clinical and laboratory disease activity using disease-specific indices and scores.
* Juvenile Systemic lupus erythematosus (JSLE): Systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) (CBC, anti-dsDNA, complement, urinalysis, protein/creatinine ratio)
* Juvenile Idiopatic Arthritis (JIA): Juvenile Arthritis Disease Activity Score (JADAS) (ESR, CRP)
* Juvenile dermatomyositis (JDM): Manual Muscle Testing (MMT) e Childhood Myositis Assessment Scale (CMAS): (CPK, transaminases, LDH)
Researcher will also perform analysis in:
Humoral immunogenicity will be assessed using serum bactericidal activity (SBA) assay with exogenous complement (baby rabbit, Pel Freez) against four test strains: H44/76 (fHBP), 5/99 (NadA), NZ98/254 (PorA), and M10713 (NHBA), from blood samples collected at D0, D28, D56, and D208. SBA assays will be conducted at the Immunology Center of the Adolfo Lutz Institute, São Paulo. Exogenous complement will be added to serially diluted serum samples, followed by the addition of a bacterial suspension. The humoral response rate induced by the vaccine, or seroconversion, will be defined by the bactericidal titer (the dilution that results in 50% bacterial killing within 60 minutes compared to the control), with titers ≥ 1:4 considered bactericidal. The geometric mean titers will be calculated using the exponential of the mean of the log-transformed concentrations.
Immunosuppressive treatments (NSAIDs, prednisone/prednisolone, intra-articular steroids, hydroxychloroquine, methotrexate, azathioprine, leflunomide, cyclosporine, tacrolimus, mycophenolate mofetil, and biologics [anti-TNF, tocilizumab, abatacept, belimumab, rituximab]) will be recorded sistematicaly.
Physical activity levels will be assessed using validated, age-appropriate methods.

开始日期2026-02-19

申办/合作机构

University of Sao Paulo General Hospital

NCT06995430

/ Completed临床3期

A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response And Safety of The Meningococcal Group B Vaccine Rmenb+Omv Nz When Administered to Healthy Participants Aged 10 To 20 Years Old, Who Were Primed During the First 2 Years Of Life

The main purpose of this study is to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years. This study focuses on individuals who were first vaccinated with rMenB+OMV NZ as infants. The primary hypothesis is that a booster dose of the vaccine will elicit a stronger immune response in these primed individuals compared to those who have never received any group B meningococcal vaccine, referred to as 'nave' participants.

开始日期2025-07-07

申办/合作机构

GSK Plc

ACTRN12623000738628

/ Recruiting临床2/3期IIT

VIRGo – Vaccine-induced Immune Responses against Gonorrhoea: A study to investigate immune response induced by the 4CMenB vaccine against gonorrhoea in healthy adults

开始日期2025-06-10

申办/合作机构

Griffith University

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的临床结果

登录后查看更多信息

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的转化医学

登录后查看更多信息

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的专利（医药）

登录后查看更多信息

377

项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的文献（医药）

2026-12-31·Human Vaccines & Immunotherapeutics

Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study

Article

作者: Lechevin, Isabelle ; Atwi, Jibran ; Keshavan, Pavitra ; Prato, Rosa ; Moraschini, Luca ; Possidente, Mariapia ; Hoberman, Alejandro ; Silas, Peter ; Lattanzi, Maria ; Martin, Judith M. ; Bosis, Samantha ; Manzella, Sara

Meningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16-18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16-18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.

2026-12-31·Human Vaccines & Immunotherapeutics

Meningococcal meningitis in India: An expert consensus on use of MCVs

Review

作者: Ravikumar, K. L. ; Panuganti, Suresh ; Biswakumar, Priya ; Gavhane, Jeetendra ; Singh, Gurpreet ; Mitra, Monjori ; Rajkumar, J. ; Dutta, Ashok Kumar ; Shah, Tushar ; Yewale, Vijay ; Kelkar, Himanshu ; Niranjan, Sanjay ; Choudhury, Jaydeep ; Dass Hazarika, Rashna ; Mitra, Niloy

Invasive meningococcal disease (IMD) is a significant but under-recognized public health challenge in India, marked by rapid progression, high mortality, and severe sequelae. This consensus document, developed from literature review, outbreak analyses, and deliberations by 14 Indian experts, highlights outbreaks from 1966 (Delhi: 616 cases, case fatality ration: CFR 20.9%) to 2022-2023 (Kolkata). Serogroup A remains predominant, with emerging serogroups C, W, and Y. Systematic review evidence shows 12.1% prevalence in epidemics (CFR 12.8%) and 0.76% in endemic settings (CFR 3.0%), though true burden is underestimated due to weak surveillance. IMD shows bimodal age distribution, highest in children < 5 y (61.8%) and adolescents. MenACWY conjugate vaccines show 95.7-99.5% seroprotection across serogroups. Experts recommend vaccination at 9-12 months with booster at 10-11 y, mandatory reporting, sentinel surveillance, and clinician awareness. The roadmap stresses awareness, short-term surveillance, and long-term data generation toward National Immunization Program inclusion.

2026-12-31·Human Vaccines & Immunotherapeutics

Meningococcal vaccination counts and public attention: A time-series study from Türkiye

Article

作者: Sayman, Ezgi Nafile ; Yıldız Silahlı, Nicel ; Dinleyici, Ener Çağrı ; Guven, Sirin ; Esen, Elif Serap ; Imdadoglu, Timucin ; Boğa, Aysun

Meningococcal infections remain a significant cause of morbidity and mortality in childhood. In Türkiye, meningococcal vaccines are not included in the national immunization program and are mainly administered through optional, self-funded services. This study aimed to examine temporal trends in meningococcal vaccination counts and to assess their association with public attention. This retrospective time-series study included children who received meningococcal vaccination at a tertiary hospital in Istanbul, Türkiye, between January 2024 and June 2025. Demographic and vaccination data were obtained from hospital records. Public attention was assessed using Google Trends data for meningococcal-related search terms. In addition, official public health announcements, professional society statements, and well-child clinic visits were considered as contextual factors. A total of 182 children were vaccinated, with a marked increase observed in 2025. Infants aged 0-24 months accounted for the majority of vaccinations. MenB was administered more frequently than MenACWY, and concomitant administration was common. Increased vaccination activity temporally coincided with peaks in Google Trends search interest, particularly for the term "meningitis," along with concurrent public health announcements. Meningococcal vaccination counts increased during periods of heightened public attention. In settings where vaccines are optional, vaccination demand may be influenced not only by epidemiological factors but also by media visibility, public awareness, and healthcare professionals' recommendations.

160

项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的新闻（医药）

2026-08-26

·搜狐新闻

M100S pl皮升级/nl纳升级/超高通量/高密度/微阵列生物芯片点样仪/疾病靶点筛选-高通量芯片点样仪(48块SBS进样板/100片标准载玻片)

英国ArrayJet公司成立于2000年，总部位于英国爱丁堡；专注于超微量生物芯片和高通量筛选应用领域的解决方案及服务；作为高通量微阵列生物芯片点样仪的制造厂商，全球客户群体广泛，从世界500强企业到顶级科研学术机构；产品介绍 M100 S 微阵列生物芯片点样仪行业领先的快速、非接触式超微量液体处理可同时进行上百种不同样品的快速点样独特的上样模块配合高通量的点样喷头，保障点样速度快、样品无污染制备高密度的蛋白质、抗体、多糖、小分子化合物、核酸等各种微阵列芯片用于高通量筛选，如自身免疫抗体、生物标记物、候选疫苗、药物靶点等技术原理独特的进样技术：相比传统的吸液喷液一体式喷头，独立的进样针和喷头的设计保证清洗更彻底，通量更高、点样更灵活。技术原理点样流程产品特点速度快：点样速度711个样片点／秒通量高：单次进行18432种不同样品的快速点样，具备128个平行喷点通道精度高： CV < 5%（可实现精准的点上点样，实现微型的点对点ELISA反应）完整的环境控制模块以及防样品蒸发保护（大幅降低点样过程中样品浓度变化）应用方向基因芯片：高通量分子互作验证、疾病功能基因检测或筛选等蛋白质芯片：高通量功能蛋白质筛选、抗原表位筛选、生物靶点筛选等多糖芯片：进行高通量糖功能学、糖蛋白、植物凝集素等研究等小分子化合物芯片：高通量药物筛选、疾病研究、疾病标志物筛选等微阵列SRPi镀金芯片：高通量分子互作研究等微孔板芯片：高通量多重因子检测、微型ELISA等微流控芯片、生物传感器芯片：药物研发、体外诊断、生物半导体研发等临床快检POCT芯片：抗原抗体检测、过敏原检测、病原微生物检测等应用案例蛋白质芯片-新冠病毒抗体研究作者：上海交通大学系统生物医学研究院应用：采用ArrayJet Super Marathon（对应新型号M 100-S）高通量微阵列生物芯片点样仪在硝化纤维素(NC)载玻片上进行病毒重组蛋白点样，该芯片涵盖了14个新冠病毒基因组所编码的蛋白质，随后孵育荧光标记的自身免疫抗体，最后用荧光芯片扫描仪进行数据分析，为新冠病毒诊断，愈后评估和疫苗开发提供有价值的线索。 SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses（Nature Communications, 2020）小分子化合物芯片-RNA酶结合位点筛选作者：美国国家癌症研究所化学生物学实验室应用：作者使用ArrayJet微阵列生物芯片点样仪将7000种小分子化合物点印到环氧修饰的玻片上，制备高通量小分子化合物微阵列芯片，通过研究发现了一种可以下调DHX15蛋白表达的化合物，该方法为新药研发过程即从靶标识别到先导化合物的发现提供了一种新的研究策略。 Competitive Microarray Screening Reveals Functional Ligands for the DHX15 RNA G-quadruplex（ACS Medicinal Chemistry Letters, 2025）多糖芯片-藻类多糖的降解机制研究作者：德国不来梅大学海洋环境科学研究中心应用：作者使用英国ArrayJet微阵列生物芯片点样仪进行多糖微阵列点样，对微生物促进藻类多糖的降解机制进行研究 Marine bacteroidetes use a conserved enzymatic cascade to digest diatom β-mannan（The ISME Journal 2023）核酸芯片-癌症相关靶点筛选作者：维也纳大学物理与化学学院应用：使用ArrayJet微阵列生物芯片点样仪将捕获探针点印在镀金芯片上，通过与荧光标记的突变型和野生型DNA进行杂交，对乳腺癌靶点进行筛选。 Detection of breast cancer-related point-mutations using screen-printed and gold-plated electrochemical sensor arrays suitable for point-of-care applications（Talanta Open 2022）典型客户发表文献： 2025.10 德国不来梅大学-马克斯·普朗克海洋微生物研究所分子生态学系 Carbohydrates, enzyme activities, and microbial communities across depth gradients in the western North Atlantic Ocean 多糖芯片 2025.10 牛津大学热带医学与全球健康中心 Long-term dynamics of cytomegalovirus-specific antibodies in a longitudinal cohort of children followed up for the first decade of life 蛋白质芯片 2025.09 美国曼切斯特大学免疫与炎症研究所 Evaluation of Immunization Route in Induction of Vaccine-Mediated Anti-Gonococcal Immune Responses in a Murine Model of Ascending Infection 蛋白质芯片 2025.09 首都医科大学，北京朝阳医院急诊医学中心，心肺脑复苏北京市重点实验室 Immunoglobulin glycosylation profiling for early identification of patients with severe influenza pneumonia 多糖凝集素芯片 2025.08 中国科学院生物物理研究所生物大分子国家实验室，深圳高新技术大学合成生物学院An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development 蛋白质芯片 2025.08 奥地利科学院分子生物技术研究所 CLEC18A interacts with sulfated glycosaminoglycans and controls clear cell renal cell carcinoma progression 多糖芯片 2025.07 挪威生命科学大学生物科学学院 Protozoal populations drive system-wide variation in the rumen microbiome 多糖芯片 2025.07 分子植物生理学，环境与生物多样性系，萨尔茨堡巴黎洛德隆大学 Arabinokinase Limits the Flux of Arabinose Into Nucleotide Sugars to Prevent Toxicity 多糖芯片 2025.07 西班牙萨拉曼卡-CSIC大学癌症研究中心 Humoral Response Profile in SARS-CoV-2 Infection: Differences across Virus Strains and Influenza 蛋白质芯片 2025.06 牛津大学热带医学与全球健康中心，肯尼亚医学研究所 A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study 蛋白质芯片 2025.06 中国科学院海洋研究所，中国科学院海洋生态与环境重点实验室 Establishment of CARD-FISH and Dot-ELISA Assays for Diagnosis of the Parasitic Dinoflagellate Hematodinium perezi 蛋白质芯片 2025.05 内蒙古农业大学生命科学学院 Lactate metabolism antagonizes antiviral innate immunity by promoting VDAC1-lactylation-mediated mtDNA release 蛋白质芯片 2025.04 中国热带农业科学院热带作物遗传资源研究所 Mutation of the Polygalacturonase Gene AcoPG3 Deferred Softening of Pineapple Fruit 蛋白质芯片 2025.04 意大利GSK全球卫生疫苗研究所 Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection 蛋白质芯片 2025.04 瑞士巴塞尔诺华制药公司生物医学研究中心 Exercise-Induced Myostimulin Enhances Muscle Function in Health and Disease 蛋白质芯片 2025.04 丹麦哥本哈根大学植物与环境科学系 Comparative transcriptomics in ferns reveals key innovations and divergent evolution of the secondary cell walls 多糖芯片 2025.04 西班牙穆尔西亚大学兽医学院食品科学与技术系 Grape Pomace Fibres as a Sustainable Fining Agent to Ensure Red Wine Safety: A First Approach in a Continuous System 多糖芯片 2025.04 曼彻斯特大学生物、医学与健康学院 Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray 蛋白质芯片 2025.03 北京大学肿瘤医院肿瘤研究所黑色素瘤与肉瘤科，癌变与转化研究教育部重点实验室 Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy 蛋白质芯片 2025.01 美国俄亥俄州立大学,生物化学研究所 Use of a small molecule microarray screen to identify inhibitors of the catalytic RNA subunit of Methanobrevibacter smithii RNase P 小分子化合物芯片 2025.01 西班牙巴利亚多利德大学医院微生物科 Assessment of Humoral Response at SARS-CoV-2 Infection by Multipronged Functional Proteomics Approaches 蛋白质芯片环亚产品环亚生物科技有限公司（APG BIO Ltd）成立于2011年，专注于引进国外创新技术和高品质仪器设备。返回搜狐，查看更多

2026-08-26

·知乎专栏

M100S pl皮升级/nl纳升级/超高通量/高密度/微阵列生物芯片点样仪/疾病靶点筛选-高通量芯片点样仪(48块SBS进样板/100片标准载玻片)

英国ArrayJet公司成立于2000年，总部位于英国爱丁堡；专注于超微量生物芯片和高通量筛选应用领域的解决方案及服务；作为高通量微阵列生物芯片点样仪的制造厂商，全球客户群体广泛，从世界500强企业到顶级科研学术机构；产品介绍M100 S 微阵列生物芯片点样仪行业领先的快速、非接触式超微量液体处理可同时进行上百种不同样品的快速点样独特的上样模块配合高通量的点样喷头，保障点样速度快、样品无污染制备高密度的蛋白质、抗体、多糖、小分子化合物、核酸等各种微阵列芯片用于高通量筛选，如自身免疫抗体、生物标记物、候选疫苗、药物靶点等技术原理独特的进样技术：相比传统的吸液喷液一体式喷头，独立的进样针和喷头的设计保证清洗更彻底，通量更高、点样更灵活。技术原理点样流程产品特点速度快：点样速度711个样片点／秒通量高：单次进行18432种不同样品的快速点样，具备128个平行喷点通道精度高： CV < 5%（可实现精准的点上点样，实现微型的点对点ELISA反应）完整的环境控制模块以及防样品蒸发保护（大幅降低点样过程中样品浓度变化）应用方向基因芯片：高通量分子互作验证、疾病功能基因检测或筛选等蛋白质芯片：高通量功能蛋白质筛选、抗原表位筛选、生物靶点筛选等多糖芯片：进行高通量糖功能学、糖蛋白、植物凝集素等研究等小分子化合物芯片：高通量药物筛选、疾病研究、疾病标志物筛选等微阵列SRPi镀金芯片：高通量分子互作研究等微孔板芯片：高通量多重因子检测、微型ELISA等微流控芯片、生物传感器芯片：药物研发、体外诊断、生物半导体研发等临床快检POCT芯片：抗原抗体检测、过敏原检测、病原微生物检测等应用案例蛋白质芯片-新冠病毒抗体研究作者：上海交通大学系统生物医学研究院应用：采用ArrayJet Super Marathon（对应新型号M 100-S）高通量微阵列生物芯片点样仪在硝化纤维素(NC)载玻片上进行病毒重组蛋白点样，该芯片涵盖了14个新冠病毒基因组所编码的蛋白质，随后孵育荧光标记的自身免疫抗体，最后用荧光芯片扫描仪进行数据分析，为新冠病毒诊断，愈后评估和疫苗开发提供有价值的线索。SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses（Nature Communications, 2020）小分子化合物芯片-RNA酶结合位点筛选作者：美国国家癌症研究所化学生物学实验室应用：作者使用ArrayJet微阵列生物芯片点样仪将7000种小分子化合物点印到环氧修饰的玻片上，制备高通量小分子化合物微阵列芯片，通过研究发现了一种可以下调DHX15蛋白表达的化合物，该方法为新药研发过程即从靶标识别到先导化合物的发现提供了一种新的研究策略。Competitive Microarray Screening Reveals Functional Ligands for the DHX15 RNA G-quadruplex（ACS Medicinal Chemistry Letters, 2025）多糖芯片-藻类多糖的降解机制研究作者：德国不来梅大学海洋环境科学研究中心应用：作者使用英国ArrayJet微阵列生物芯片点样仪进行多糖微阵列点样，对微生物促进藻类多糖的降解机制进行研究Marine bacteroidetes use a conserved enzymatic cascade to digest diatom β-mannan（The ISME Journal 2023）核酸芯片-癌症相关靶点筛选作者：维也纳大学物理与化学学院应用：使用ArrayJet微阵列生物芯片点样仪将捕获探针点印在镀金芯片上，通过与荧光标记的突变型和野生型DNA进行杂交，对乳腺癌靶点进行筛选。Detection of breast cancer-related point-mutations using screen-printed and gold-plated electrochemical sensor arrays suitable for point-of-care applications（Talanta Open 2022）典型客户发表文献：2025.10 德国不来梅大学-马克斯·普朗克海洋微生物研究所分子生态学系 Carbohydrates, enzyme activities, and microbial communities across depth gradients in the western North Atlantic Ocean 多糖芯片2025.10 牛津大学热带医学与全球健康中心 Long-term dynamics of cytomegalovirus-specific antibodies in a longitudinal cohort of children followed up for the first decade of life 蛋白质芯片2025.09 美国曼切斯特大学免疫与炎症研究所 Evaluation of Immunization Route in Induction of Vaccine-Mediated Anti-Gonococcal Immune Responses in a Murine Model of Ascending Infection 蛋白质芯片2025.09 首都医科大学，北京朝阳医院急诊医学中心，心肺脑复苏北京市重点实验室 Immunoglobulin glycosylation profiling for early identification of patients with severe influenza pneumonia 多糖凝集素芯片2025.08 中国科学院生物物理研究所生物大分子国家实验室，深圳高新技术大学合成生物学院An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development 蛋白质芯片2025.08 奥地利科学院分子生物技术研究所 CLEC18A interacts with sulfated glycosaminoglycans and controls clear cell renal cell carcinoma progression 多糖芯片2025.07 挪威生命科学大学生物科学学院 Protozoal populations drive system-wide variation in the rumen microbiome 多糖芯片2025.07 分子植物生理学，环境与生物多样性系，萨尔茨堡巴黎洛德隆大学 Arabinokinase Limits the Flux of Arabinose Into Nucleotide Sugars to Prevent Toxicity 多糖芯片2025.07 西班牙萨拉曼卡-CSIC大学癌症研究中心 Humoral Response Profile in SARS-CoV-2 Infection: Differences across Virus Strains and Influenza 蛋白质芯片2025.06 牛津大学热带医学与全球健康中心，肯尼亚医学研究所 A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study 蛋白质芯片2025.06 中国科学院海洋研究所，中国科学院海洋生态与环境重点实验室 Establishment of CARD-FISH and Dot-ELISA Assays for Diagnosis of the Parasitic Dinoflagellate Hematodinium perezi 蛋白质芯片2025.05 内蒙古农业大学生命科学学院 Lactate metabolism antagonizes antiviral innate immunity by promoting VDAC1-lactylation-mediated mtDNA release 蛋白质芯片2025.04 中国热带农业科学院热带作物遗传资源研究所 Mutation of the Polygalacturonase Gene AcoPG3 Deferred Softening of Pineapple Fruit 蛋白质芯片2025.04 意大利GSK全球卫生疫苗研究所 Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection 蛋白质芯片2025.04 瑞士巴塞尔诺华制药公司生物医学研究中心 Exercise-Induced Myostimulin Enhances Muscle Function in Health and Disease 蛋白质芯片2025.04 丹麦哥本哈根大学植物与环境科学系 Comparative transcriptomics in ferns reveals key innovations and divergent evolution of the secondary cell walls 多糖芯片2025.04 西班牙穆尔西亚大学兽医学院食品科学与技术系 Grape Pomace Fibres as a Sustainable Fining Agent to Ensure Red Wine Safety: A First Approach in a Continuous System 多糖芯片2025.04 曼彻斯特大学生物、医学与健康学院 Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray 蛋白质芯片2025.03 北京大学肿瘤医院肿瘤研究所黑色素瘤与肉瘤科，癌变与转化研究教育部重点实验室 Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy 蛋白质芯片2025.01 美国俄亥俄州立大学,生物化学研究所 Use of a small molecule microarray screen to identify inhibitors of the catalytic RNA subunit of Methanobrevibacter smithii RNase P 小分子化合物芯片2025.01 西班牙巴利亚多利德大学医院微生物科 Assessment of Humoral Response at SARS-CoV-2 Infection by Multipronged Functional Proteomics Approaches 蛋白质芯片环亚产品环亚生物科技有限公司（APG BIO Ltd）成立于2011年，专注于引进国外创新技术和高品质仪器设备。

2026-08-26

·微信

M100S pl皮升级/nl纳升级/超高通量/高密度/微阵列生物芯片点样仪/疾病靶点筛选-高通量芯片点样仪(48块SBS进样板/100片标准载玻片)

英国ArrayJet公司成立于2000年，总部位于英国爱丁堡；专注于超微量生物芯片和高通量筛选应用领域的解决方案及服务；作为高通量微阵列生物芯片点样仪的制造厂商，全球客户群体广泛，从世界500强企业到顶级科研学术机构；产品介绍 M100 S 微阵列生物芯片点样仪行业领先的快速、非接触式超微量液体处理可同时进行上百种不同样品的快速点样独特的上样模块配合高通量的点样喷头，保障点样速度快、样品无污染制备高密度的蛋白质、抗体、多糖、小分子化合物、核酸等各种微阵列芯片用于高通量筛选，如自身免疫抗体、生物标记物、候选疫苗、药物靶点等技术原理独特的进样技术：相比传统的吸液喷液一体式喷头，独立的进样针和喷头的设计保证清洗更彻底，通量更高、点样更灵活。技术原理点样流程产品特点速度快：点样速度711个样片点／秒通量高：单次进行18432种不同样品的快速点样，具备128个平行喷点通道精度高： CV < 5%（可实现精准的点上点样，实现微型的点对点ELISA反应）完整的环境控制模块以及防样品蒸发保护（大幅降低点样过程中样品浓度变化）应用方向基因芯片：高通量分子互作验证、疾病功能基因检测或筛选等蛋白质芯片：高通量功能蛋白质筛选、抗原表位筛选、生物靶点筛选等多糖芯片：进行高通量糖功能学、糖蛋白、植物凝集素等研究等小分子化合物芯片：高通量药物筛选、疾病研究、疾病标志物筛选等微阵列SRPi镀金芯片：高通量分子互作研究等微孔板芯片：高通量多重因子检测、微型ELISA等微流控芯片、生物传感器芯片：药物研发、体外诊断、生物半导体研发等临床快检POCT芯片：抗原抗体检测、过敏原检测、病原微生物检测等应用案例蛋白质芯片-新冠病毒抗体研究作者：上海交通大学系统生物医学研究院应用：采用ArrayJet Super Marathon（对应新型号M 100-S）高通量微阵列生物芯片点样仪在硝化纤维素(NC)载玻片上进行病毒重组蛋白点样，该芯片涵盖了14个新冠病毒基因组所编码的蛋白质，随后孵育荧光标记的自身免疫抗体，最后用荧光芯片扫描仪进行数据分析，为新冠病毒诊断，愈后评估和疫苗开发提供有价值的线索。 SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses（Nature Communications, 2020）小分子化合物芯片-RNA酶结合位点筛选作者：美国国家癌症研究所化学生物学实验室应用：作者使用ArrayJet微阵列生物芯片点样仪将7000种小分子化合物点印到环氧修饰的玻片上，制备高通量小分子化合物微阵列芯片，通过研究发现了一种可以下调DHX15蛋白表达的化合物，该方法为新药研发过程即从靶标识别到先导化合物的发现提供了一种新的研究策略。 Competitive Microarray Screening Reveals Functional Ligands for the DHX15 RNA G-quadruplex（ACS Medicinal Chemistry Letters, 2025）多糖芯片-藻类多糖的降解机制研究作者：德国不来梅大学海洋环境科学研究中心应用：作者使用英国ArrayJet微阵列生物芯片点样仪进行多糖微阵列点样，对微生物促进藻类多糖的降解机制进行研究 Marine bacteroidetes use a conserved enzymatic cascade to digest diatom β-mannan（The ISME Journal 2023）核酸芯片-癌症相关靶点筛选作者：维也纳大学物理与化学学院应用：使用ArrayJet微阵列生物芯片点样仪将捕获探针点印在镀金芯片上，通过与荧光标记的突变型和野生型DNA进行杂交，对乳腺癌靶点进行筛选。 Detection of breast cancer-related point-mutations using screen-printed and gold-plated electrochemical sensor arrays suitable for point-of-care applications（Talanta Open 2022）典型客户发表文献： 2025.10 德国不来梅大学-马克斯·普朗克海洋微生物研究所分子生态学系 Carbohydrates, enzyme activities, and microbial communities across depth gradients in the western North Atlantic Ocean 多糖芯片 2025.10 牛津大学热带医学与全球健康中心 Long-term dynamics of cytomegalovirus-specific antibodies in a longitudinal cohort of children followed up for the first decade of life 蛋白质芯片 2025.09 美国曼切斯特大学免疫与炎症研究所 Evaluation of Immunization Route in Induction of Vaccine-Mediated Anti-Gonococcal Immune Responses in a Murine Model of Ascending Infection 蛋白质芯片 2025.09 首都医科大学，北京朝阳医院急诊医学中心，心肺脑复苏北京市重点实验室 Immunoglobulin glycosylation profiling for early identification of patients with severe influenza pneumonia 多糖凝集素芯片 2025.08 中国科学院生物物理研究所生物大分子国家实验室，深圳高新技术大学合成生物学院An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development 蛋白质芯片 2025.08 奥地利科学院分子生物技术研究所 CLEC18A interacts with sulfated glycosaminoglycans and controls clear cell renal cell carcinoma progression 多糖芯片 2025.07 挪威生命科学大学生物科学学院 Protozoal populations drive system-wide variation in the rumen microbiome 多糖芯片 2025.07 分子植物生理学，环境与生物多样性系，萨尔茨堡巴黎洛德隆大学 Arabinokinase Limits the Flux of Arabinose Into Nucleotide Sugars to Prevent Toxicity 多糖芯片 2025.07 西班牙萨拉曼卡-CSIC大学癌症研究中心 Humoral Response Profile in SARS-CoV-2 Infection: Differences across Virus Strains and Influenza 蛋白质芯片 2025.06 牛津大学热带医学与全球健康中心，肯尼亚医学研究所 A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study 蛋白质芯片 2025.06 中国科学院海洋研究所，中国科学院海洋生态与环境重点实验室 Establishment of CARD-FISH and Dot-ELISA Assays for Diagnosis of the Parasitic Dinoflagellate Hematodinium perezi 蛋白质芯片 2025.05 内蒙古农业大学生命科学学院 Lactate metabolism antagonizes antiviral innate immunity by promoting VDAC1-lactylation-mediated mtDNA release 蛋白质芯片 2025.04 中国热带农业科学院热带作物遗传资源研究所 Mutation of the Polygalacturonase Gene AcoPG3 Deferred Softening of Pineapple Fruit 蛋白质芯片 2025.04 意大利GSK全球卫生疫苗研究所 Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection 蛋白质芯片 2025.04 瑞士巴塞尔诺华制药公司生物医学研究中心 Exercise-Induced Myostimulin Enhances Muscle Function in Health and Disease 蛋白质芯片 2025.04 丹麦哥本哈根大学植物与环境科学系 Comparative transcriptomics in ferns reveals key innovations and divergent evolution of the secondary cell walls 多糖芯片 2025.04 西班牙穆尔西亚大学兽医学院食品科学与技术系 Grape Pomace Fibres as a Sustainable Fining Agent to Ensure Red Wine Safety: A First Approach in a Continuous System 多糖芯片 2025.04 曼彻斯特大学生物、医学与健康学院 Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray 蛋白质芯片 2025.03 北京大学肿瘤医院肿瘤研究所黑色素瘤与肉瘤科，癌变与转化研究教育部重点实验室 Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy 蛋白质芯片 2025.01 美国俄亥俄州立大学,生物化学研究所 Use of a small molecule microarray screen to identify inhibitors of the catalytic RNA subunit of Methanobrevibacter smithii RNase P 小分子化合物芯片 2025.01 西班牙巴利亚多利德大学医院微生物科 Assessment of Humoral Response at SARS-CoV-2 Infection by Multipronged Functional Proteomics Approaches 蛋白质芯片环亚产品环亚生物科技有限公司（APG BIO Ltd）成立于2011年，专注于引进国外创新技术和高品质仪器设备。主推产品包括全自动DNA核酸脉冲场电泳回收仪--美国Sage Science 代替手工切胶和磁珠，用于二代／三代／超长测序文库、常规分子实验的精准回收 24通道明场实时活细胞成像分析仪--德国innoME 6/24孔板分组对比实验，用于细胞、类器官的生长监测、划痕迁移、培养优化等超高通量、高密度微阵列生物芯片点样仪 --英国ArrayJet 单次可喷点上万种生物样品，制备最多1000张高密度生物芯片，用于高通量筛选皮升、纳升级高精度微阵列生物芯片点样仪--德国M2 Automation 生物传感器、微流控、微孔板、微柱、微针、覆膜、POCT芯片等点样，可灵活定制超高通量 SPRi分子互作仪--美国Plexera 表面等离子共振成像技术，无标记实时动力学检测，最多同时检测3840对分子互作超高精度组织原位蛋白功能定量分析系统--西班牙Hawk Biosystems 小于10nm距离的蛋白质相互作用定量验证，用于互作、翻译后修饰、肿瘤免疫等毛细管电泳生物制药分析系统--荷兰Prince technologies 纳升级全自动压力浓缩进样，全程控温，用于蛋白纯度／等电点测定、制药质控等更多产品咨询,请联系我们：环亚生物科技有限公司地址：上海市松江区莘砖公路518号9幢502室电话：021-54583565 邮箱：marketing@apgbio.com 官网：www.apgbio.com 扫码关注我们产品咨询 | 资料获取线上报修 | 简历投递

疫苗

100 项与 B群脑膜炎球菌疫苗(Novartis Pharma AG) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AH09	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
脑膜炎	加拿大	GSK Plc	2014-02-26
脑膜炎球菌感染	欧盟	GSK Plc	2013-01-13
脑膜炎球菌感染	冰岛	GSK Plc	2013-01-13
脑膜炎球菌感染	列支敦士登	GSK Plc	2013-01-13
脑膜炎球菌感染	挪威	GSK Plc	2013-01-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流行性脑脊髓膜炎	临床3期	奥地利	GSK Plc	2008-03-01
流行性脑脊髓膜炎	临床3期	捷克	GSK Plc	2008-03-01
流行性脑脊髓膜炎	临床3期	芬兰	GSK Plc	2008-03-01
流行性脑脊髓膜炎	临床3期	德国	GSK Plc	2008-03-01
流行性脑脊髓膜炎	临床3期	意大利	GSK Plc	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03621670 (CTgov)	临床3期	脑膜炎球菌感染	1,196	Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)+Prevnar 20+Hiberix+Rotarix+Varivax+Prevnar13+Pediarix+M-M-R II (MenB+PCV Group)	網繭壓積糧積窪鹽壓鹽 = 鬱範艱壓繭願構顧鹽醖廠蓋衊糧壓鬱選餘鹽糧 (築遞襯構製衊窪廠顧壓, 淵廠糧觸壓壓積衊顧鬱 ~ 衊醖鹽觸觸簾鑰糧鏇醖) 更多	-	2026-02-10
				Placebo (saline water)+Prevnar 20+Hiberix+Rotarix+Varivax+Prevnar13+Pediarix+M-M-R II (Placebo+PCV Group)	鏇齋糧顧衊選遞選鬱衊 = 糧築觸鏇廠選範壓鹽範顧築憲積膚廠憲衊壓繭 (蓋糧獵窪壓廠鹹願鏇簾, 鹹淵簾艱鬱衊願窪鏇鏇 ~ 範淵鑰顧鹹艱構憲淵範) 更多
NCT04318548 (CTgov)	临床3期	脑膜炎球菌感染	945	Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)+Placebo+Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid) (MenB+MenACWY Group)	齋遞襯艱壓鏇糧顧鏇範 = 獵襯襯獵艱範簾鹽壓蓋鑰鏇鬱簾鏇積蓋餘蓋廠 (範簾鹹鏇鑰壓鹹窪積觸, 繭餘簾簾範網醖齋憲遞 ~ 顧鏇鹹齋獵壓壓鏇鏇願) 更多	-	2025-03-04
				Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)+Placebo+Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid) (MenB Group)	齋遞襯艱壓鏇糧顧鏇範 = 窪築鬱夢壓範獵膚膚憲鑰鏇鬱簾鏇積蓋餘蓋廠 (範簾鹹鏇鑰壓鹹窪積觸, 繭廠鬱鹹積築齋鹽憲窪 ~ 衊顧觸餘壓網膚選餘襯) 更多
NCT04722003 (CTgov)	临床2期	淋病	52	Meningococcal Group B Vaccine (4CMenB)	齋顧網蓋鑰製遞膚鹽積(鹹廠蓋憲願選觸衊遞觸) = 衊鹽鹽蓋蓋憲範糧襯廠築襯繭簾窪艱觸範網夢 (襯壓簾遞淵餘蓋衊糧繭, 廠蓋膚遞觸憲製鹹齋顧 ~ 製鹽鬱鹹製觸齋憲廠築) 更多	-	2024-11-05
				Placebo (Placebo)	齋顧網蓋鑰製遞膚鹽積(鹹廠蓋憲願選觸衊遞觸) = 鹽遞衊積齋築窪餘蓋餘築襯繭簾窪艱觸範網夢 (襯壓簾遞淵餘蓋衊糧繭, 膚鹽選築鏇鏇鏇襯壓構 ~ 艱襯夢醖淵網蓋襯鬱糧) 更多
NCT03125616 (Pubmed \| Arch Dis Child)	临床4期	早产儿疾病	129	4CMenBomponent meningococcal B vaccine (4CMenB 2+1 schedule)	顧鹹衊鬱範憲齋築醖選(獵選構選選淵鑰憲製繭) = 糧繭餘簾網繭遞獵獵醖壓艱醖鬱網廠膚範範構 (鬱獵積鹽蓋窪蓋窪顧繭 )	积极	2024-11-01
				4CMenBomponent meningococcal B vaccine (4CMenB 3+1 schedule)	顧鹹衊鬱範憲齋築醖選(獵選構選選淵鑰憲製繭) = 鹽繭淵選願膚製觸襯襯壓艱醖鬱網廠膚範範構 (鬱獵積鹽蓋窪蓋窪顧繭 )
NCT03493919 (CTgov)	临床4期	流行性脑脊髓膜炎	1,021	rMenB+OMV NZ vaccine (rMenB+OMV NZ Group)	範糧膚糧窪廠淵醖製網 = 鬱簾餘夢積蓋壓窪願構廠壓網齋衊鹽網鑰獵選 (艱糧艱築構獵顧網鑰鑰, 獵簾衊襯積鹽衊網鹽淵 ~ 鹹獵構願繭獵艱壓壓夢) 更多	-	2023-07-17
				Y Conjugate Vaccine (MenACWY) (MenACWY 1 Group)	範糧膚糧窪廠淵醖製網 = 獵顧鏇鹽觸鑰製鏇製糧廠壓網齋衊鹽網鑰獵選 (艱糧艱築構獵顧網鑰鑰, 醖齋醖窪繭窪獵範醖鏇 ~ 範醖遞顧簾壓糧製鏇顧) 更多
NCT04094883 (4CMenB, CTgov)	临床4期	淋病	11	Meningococcal Group B Vaccine	淵淵積糧鏇選憲網鬱夢(積繭構構構艱選艱淵襯) = 築衊壓廠齋獵蓋製膚範鹽糧構獵齋製糧鹹鹽築 (醖鏇鹽積鬱遞壓鹹顧範, 鹹簾選餘網遞淵餘艱壓 ~ 範獵鹽獵夢願淵廠蓋衊) 更多	-	2021-07-15
NCT03089086 (Pubmed \| Clin Infect Dis)	临床4期	侵袭性脑膜炎球菌病	34,489	meningococcal B vaccine (Control group (not vaccinated))	淵淵夢衊鬱夢鹹願醖遞(願壓範醖選鏇構構鹹壓) = 衊鏇醖壓築築簾蓋糧糧廠襯窪夢獵鬱膚餘鏇糧 (鏇積鹹膚遞鹹壓遞淵艱 )	积极	2021-02-15
NCT03089086 (Pubmed \| Vaccine)	临床4期	-	34,489	4CMenB vaccine	鬱齋選繭構襯鹹構艱餘(繭艱衊構艱鑰願壓願餘) = 繭鏇網築窪遞鏇艱餘鹹壓製鬱鑰襯選選築積獵 (夢遞窪廠顧鏇鏇遞衊鬱, 0.28 ~ 0.39) 更多	-	2020-08-18
NCT03089086 (Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床4期	脑膜炎球菌感染	34,489	4CMenB	鑰窪構簾膚膚醖願鏇範(窪蓋夢範夢範範窪窪簾) = 選衊艱窪觸窪淵範夢齋顧衊獵選築繭憲餘壓範 (製淵鏇繭獵鏇蓋衊餘窪 )	不佳	2020-01-23
				No Intervention	鑰窪構簾膚膚醖願鏇範(窪蓋夢範夢範範窪窪簾) = 鏇餘糧觸築糧夢蓋艱積顧衊獵選築繭憲餘壓範 (製淵鏇繭獵鏇蓋衊餘窪 )
NCT02946385 (CTgov)	临床2期	脑膜炎球菌感染	604	MenABCWY (ABCWY_0_2)	繭淵窪選夢觸鹹網網鏇 = 繭積鹽構餘蓋構製網窪憲願夢餘糧鹽餘憲膚簾 (鏇簾鏇遞獵襯壓獵網鑰, 淵艱壓膚獵糧觸鹽顧蓋 ~ 蓋築鏇餘鬱餘願鹽襯廠) 更多	-	2019-08-20
				MenABCWY (ABCWY_0_2_6)	繭淵窪選夢觸鹹網網鏇 = 觸憲鹹範鏇夢簾繭繭艱憲願夢餘糧鹽餘憲膚簾 (鏇簾鏇遞獵襯壓獵網鑰, 遞餘艱衊廠簾醖遞鏇壓 ~ 積夢膚構遞襯壓憲鑰鹹) 更多